涉及丙烯酰芬太尼及其他新型设计芬太尼的中毒——瑞典STRIDA项目结果
该报告来自瑞典STRIDA项目,描述2016年4月至10月经分析确认的11例涉及新型芬太尼类似物丙烯酰芬太尼、4-氯异丁酰芬太尼(4Cl-iBF)、4-氟异丁酰芬太尼(4F-iBF)和四氢呋喃芬太尼(THF-F)的中毒。患者年龄19-51岁(中位28岁),91%为男性;6例(55%)在急诊科监护,5例收入ICU。典型临床特征为意识下降、呼吸抑制和瞳孔缩小。8例使用纳洛酮拮抗阿片效应;1例4F-iBF阳性患者最终死于脑水肿。血清丙烯酰芬太尼浓度(n=8)为0.5-2.1 ng/mL(中位0.9 ng/mL)。
要点
- 11例经分析确认的丙烯酰芬太尼等新型芬太尼类似物中毒中,6例(55%)在急诊科监护、5例收入ICU,提示此类中毒可需重症监护。
- 典型临床特征为意识下降、呼吸抑制和瞳孔缩小;8例使用纳洛酮拮抗阿片效应,纳洛酮可有效逆转阿片症状。
- 1例4F-iBF阳性患者最终死于脑水肿。
- 血清丙烯酰芬太尼浓度(n=8)为0.5-2.1 ng/mL(中位0.9 ng/mL),尿浓度(n=9)为0.2-10.5 μg/mmol肌酐(均值4.6、中位5.2)。
- 2016年初患者带入医院或经测试购买、标称含丙烯酰芬太尼的鼻喷雾剂,实际被证明含芬太尼。
适用人群与场景
- 瑞典急诊科或ICU就诊、疑似新型精神活性物质暴露且需要住院治疗的患者被邀请加入STRIDA项目。
- 本报告纳入2016年4月至10月经分析确认涉及丙烯酰芬太尼、4Cl-iBF、4F-iBF或THF-F中毒的11例患者,年龄19-51岁(中位28岁),91%为男性。
处置流程与药物剂量
- 8例使用纳洛酮拮抗阿片效应,纳洛酮可有效逆转阿片症状。
- 6例(55%)在急诊科监护,5例收入ICU接受急性与重症医院支持治疗。
红旗征与不能漏的情况
- 意识下降、呼吸抑制和瞳孔缩小为典型临床特征,提示潜在危及生命的阿片毒性。
- 1例4F-iBF阳性患者最终死于脑水肿。
研究设计与关键结果
- 瑞典STRIDA项目报告,2016年4月至10月经分析确认11例中毒:丙烯酰芬太尼8例、丙烯酰芬太尼合并4Cl-iBF 1例、4F-iBF 1例、THF-F 1例。
- 患者年龄19-51岁(中位28岁),91%为男性;6例(55%)在急诊科监护,5例收入ICU。
- 典型临床特征为意识下降、呼吸抑制和瞳孔缩小;8例使用纳洛酮拮抗阿片效应;1例4F-iBF阳性患者最终死于脑水肿。
- 血清丙烯酰芬太尼浓度(n=8)0.5-2.1 ng/mL(中位0.9 ng/mL),尿浓度(n=9)0.2-10.5 μg/mmol肌酐(均值4.6、中位5.2)。
- 4Cl-iBF、4F-iBF和THF-F各1例,血清浓度5-45 ng/mL、尿浓度11-136 μg/mmol肌酐,高于丙烯酰芬太尼组。
- 5例同时检出其他新型精神活性物质(如氟硝唑仑)和/或经典药物。
- 2016年初患者带入医院或经测试购买、标称含丙烯酰芬太尼的鼻喷雾剂,被证明实际含芬太尼。
证据类型、等级与局限
- 证据类型:来自瑞典STRIDA项目的前瞻性病例系列报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似新型精神活性物质暴露的急诊或ICU患者,应考虑到芬太尼类似物中毒可能,典型表现为意识下降、呼吸抑制和瞳孔缩小。
- 纳洛酮可有效逆转此类芬太尼类似物引起的阿片症状,本组8例使用纳洛酮拮抗阿片效应。
- 标称含丙烯酰芬太尼的鼻喷雾剂可能实际含芬太尼,检测结果与标称成分不一致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The number of new psychoactive substances (NPS) introduced through the online recreational drugs market increases continuously. This report from the Swedish STRIDA project describes analytically confirmed intoxications involving the novel fentanyl analogs acrylfentanyl, 4-chloroisobutyrfentanyl (4Cl-iBF), 4-fluoroisobutyrfentanyl (4F-iBF), and tetrahydrofuranfentanyl (THF-F), and cyclopentylfentanyl in a drug product.
METHODS: Patients with suspected NPS exposure presenting in emergency departments (ED) or intensive care units (ICU) in Sweden and requiring hospital care are invited to the STRIDA project. NPS analysis of serum and urine samples was performed by multi-component liquid chromatography-mass spectrometry. Data on clinical features were retrieved from telephone consultations with the Swedish Poisons Information Centre and from medical records.
RESULTS: Between April and October 2016, eleven intoxications involving acrylfentanyl (8 cases), acrylfentanyl together with 4Cl-iBF (1), 4F-iBF (1), and THF-F (1) were analytically confirmed. Patients were aged 19-51 (median 28) years and 91% were men. Six (55%) were monitored at the ED, and five admitted to the ICU. Typical clinical features were decreased consciousness, respiratory depression, and miosis. In 8 cases, the antidote naloxone was administered to counter the opioid effects. The 4F-iBF positive patient eventually died of brain edema. The serum acrylfentanyl concentration (n = 8) ranged 0.5-2.1 (median 0.9) ng/mL, and in urine (n = 9) 0.2-10.5 (mean 4.6, median 5.2) μg/mmol creatinine. For 4Cl-iBF, 4F-iBF, and THF-F (n = 1 each), higher serum (5-45 ng/mL) and urine (11-136 μg/mmol creatinine) concentrations were found. Other NPS (e.g., flunitrazolam) and/or classical drugs were detected in five cases. In early 2016, nasal sprays with a claimed content of acrylfentanyl brought to hospital by patients or obtained by test purchase were demonstrated to instead contain fentanyl.
CONCLUSIONS: Potentially life-threatening opioid toxicity was seen in 11 acute intoxications involving the fentanyl analogs acrylfentanyl, 4Cl-iBF, 4F-iBF, and THF-F, which are available through open Internet trading. All patients were supported with acute and intensive hospital care, and naloxone was effective to reverse the opioid symptoms. One patient died of brain edema.
参考来源
- Helander A, Bäckberg M, Signell P, et al. Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project. Clin Toxicol (Phila). 2017. PMID: 28349714. doi:10.1080/15563650.2017.1303141
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。